Impact of medication adherence on hospitalization risk and healthcare cost
- PMID: 15908846
- DOI: 10.1097/01.mlr.0000163641.86870.af
Impact of medication adherence on hospitalization risk and healthcare cost
Abstract
Objective: The objective of this study was to evaluate the impact of medication adherence on healthcare utilization and cost for 4 chronic conditions that are major drivers of drug spending: diabetes, hypertension, hypercholesterolemia, and congestive heart failure.
Research design: The authors conducted a retrospective cohort observation of patients who were continuously enrolled in medical and prescription benefit plans from June 1997 through May 1999. Patients were identified for disease-specific analysis based on claims for outpatient, emergency room, or inpatient services during the first 12 months of the study. Using an integrated analysis of administrative claims data, medical and drug utilization were measured during the 12-month period after patient identification. Medication adherence was defined by days' supply of maintenance medications for each condition.
Patients: The study consisted of a population-based sample of 137,277 patients under age 65.
Measures: Disease-related and all-cause medical costs, drug costs, and hospitalization risk were measured. Using regression analysis, these measures were modeled at varying levels of medication adherence.
Results: For diabetes and hypercholesterolemia, a high level of medication adherence was associated with lower disease-related medical costs. For these conditions, higher medication costs were more than offset by medical cost reductions, producing a net reduction in overall healthcare costs. For diabetes, hypercholesterolemia, and hypertension, cost offsets were observed for all-cause medical costs at high levels of medication adherence. For all 4 conditions, hospitalization rates were significantly lower for patients with high medication adherence.
Conclusions: For some chronic conditions, increased drug utilization can provide a net economic return when it is driven by improved adherence with guidelines-based therapy.
Comment in
-
The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know.Med Care. 2005 Jun;43(6):517-20. doi: 10.1097/01.mlr.0000166617.68751.5f. Med Care. 2005. PMID: 15908845 No abstract available.
Similar articles
-
Impact of type 2 diabetes medication cost sharing on patient outcomes and health plan costs.Am J Manag Care. 2016 Jun;22(6):433-40. Am J Manag Care. 2016. PMID: 27355811
-
Medication costs, adherence, and health outcomes among Medicare beneficiaries.Health Aff (Millwood). 2003 Jul-Aug;22(4):220-9. doi: 10.1377/hlthaff.22.4.220. Health Aff (Millwood). 2003. PMID: 12889771
-
Costs and utilization associated with pharmaceutical adherence in a diabetic population.Am J Manag Care. 2004 Feb;10(2 Pt 2):144-51. Am J Manag Care. 2004. PMID: 15005507
-
Prescription drug cost sharing: associations with medication and medical utilization and spending and health.JAMA. 2007 Jul 4;298(1):61-9. doi: 10.1001/jama.298.1.61. JAMA. 2007. PMID: 17609491 Free PMC article. Review.
-
Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review.PLoS One. 2014 Mar 25;9(3):e89168. doi: 10.1371/journal.pone.0089168. eCollection 2014. PLoS One. 2014. PMID: 24667163 Free PMC article. Review.
Cited by
-
Highlighting differences between conditional and unconditional quantile regression approaches through an application to assess medication adherence.Health Econ. 2013 Sep;22(9):1052-70. doi: 10.1002/hec.2927. Epub 2013 Apr 25. Health Econ. 2013. PMID: 23616446 Free PMC article.
-
Doctors' views and strategies to improve patients' adherence to medication.Hormones (Athens). 2021 Sep;20(3):603-611. doi: 10.1007/s42000-021-00294-2. Epub 2021 Apr 29. Hormones (Athens). 2021. PMID: 33914291 Free PMC article. No abstract available.
-
Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study.Wien Klin Wochenschr. 2015 Mar;127(5-6):203-9. doi: 10.1007/s00508-015-0748-0. Epub 2015 Mar 5. Wien Klin Wochenschr. 2015. PMID: 25739649
-
Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study.BMJ Open. 2013 Apr 30;3(4):e002348. doi: 10.1136/bmjopen-2012-002348. Print 2013. BMJ Open. 2013. PMID: 23633415 Free PMC article.
-
Associations of Renin-Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study.J Am Heart Assoc. 2020 Sep;9(17):e016094. doi: 10.1161/JAHA.119.016094. Epub 2020 Aug 26. J Am Heart Assoc. 2020. PMID: 32844732 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical